Vertex Pharmaceuticals (MEX:VRTX) Inventories, Finished Goods: MXN4,615 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VRTX Vertex Pharmaceuticals Inc MEX:VRTX
91 GF Score
Price MXN8,530.00
GF Value MXN8,880.23
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Inventories, Finished Goods?

Vertex Pharmaceuticals MEX:VRTX 91 Inventories, Finished Goods is MXN4,615 Mil as of Mar. 2026. GuruFocus rates MEX:VRTX with a GF Score™ of 91/100 and a GF Value™ of MXN8,880.23 (Fairly Valued). The stock has 5 warning signs investors should review.

Vertex Pharmaceuticals's quarterly finished goods declined from Sep. 2025 (MXN4,623 Mil) to Dec. 2025 (MXN4,143 Mil) but then increased from Dec. 2025 (MXN4,143 Mil) to Mar. 2026 (MXN4,615 Mil).

Vertex Pharmaceuticals's annual finished goods increased from Dec. 2023 (MXN2,292 Mil) to Dec. 2024 (MXN3,850 Mil) and increased from Dec. 2024 (MXN3,850 Mil) to Dec. 2025 (MXN4,143 Mil).

Vertex Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Inventories, Finished Goods Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,778.56 3,154.45 2,291.52 3,849.96 4,143.11

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,255.31 4,035.10 4,622.74 4,143.11 4,614.57
MEX:VRTX
91GF Score
Vertex Pharmaceuticals Inc MEX:VRTX
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of MXN4,615 Mil mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Inventories, Finished Goods of MXN4,615 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Inventories, Finished Goods too high?
Vertex Pharmaceuticals' current Inventories, Finished Goods is MXN4,615 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Inventories, Finished Goods compare to REGN and ALNY?
Vertex Pharmaceuticals' Inventories, Finished Goods of MXN4,615 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Inventories, Finished Goods is MXN4,615 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,880.23, compared to a current price of MXN8,530.00 — trading 3.9% below its estimated fair value. The current Inventories, Finished Goods is MXN4,615 Mil. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Inventories, Finished Goods is MXN4,615 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of MXN8,530.00 is trading 3.9% below its estimated GF Value™ of MXN8,880.23. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:VRTX:

  • Inventories, Finished Goods: MXN4,615 Mil
  • GF Value™: MXN8,880.23 vs. price of MXN8,530.00 (3.9% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score

Get the complete analysis for MEX:VRTX

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN8,530.00
Price
MXN8,880.23
GF Value